

Fig. 1

DOTAP



DODAP



EPC




Fig. 2





Fig. 3

Aerosol bolus dosing of well-differentiated human bronchial epithelial cultures with TR mRNA (12 ug)



Aerosol delivery to well-differentiated human bronchial epithelial cultures with TR mRNA (4 ug)




Fig. 4



4A3-SC7 20% DOBAP
0.4 mg RNA
2.0 mg RNA
6.0 mg RNA
33.3 p/mm²
33.3 p/mm²
66.6 p/mm²
4A3-SC7 40% DOTAP
0.4 mg RNA
2.0 mg RNA
~7.3 mg RNA (Failed Nebulization)
33.3 p/mm²
33.3 p/mm²
66.6 p/mm²
5A2-SC8
0.4 mg RNA
2.0 mg RNA
~1.8 mg RNA (Failed Nebulization)
33.3 p/mm²
33.3 p/mm²
66.6 p/mm²
5A2-SC8 40% DOTAP

Fig. 5



Cell Toxicity in hBEs
Single dose (apical bolus, 12 ug)
% LDH release
20
15
10
5
0
pre-treatment
24 hrs post-treatment
50% DOTAP
40% EPC1
20% EPC2
20% DODAP

Fig. 6



Size
Size (nm)
140
120
100
80
60
40
20
0
0 7 14 21 28
Days
PDI
0.15
0.10
0.05
0.00
0 7 14 21 28
Days
Zeta
mV
4
2
0
-2
-4
0 7 14 21 28
Days
EE
%
102
100
98
96
94
92
90
0 7 14 21 28
Days
Liver SORT
Lung SORT

Fig. 7



Tissue-specific radiance over time in mice
Lung SORT Average
Liver
Lung
Spleen
p/s/sec/cm²/sr
2×10⁴
1.5×10⁴
1×10⁴
5×10³
0
8 7 14 21 28 8 7 14 21 28 8 7 14 21 28
Days
Mice injected with 0.1 mg/kg, IV, IVIS at 5h

Fig. 8



Day 0
Day 7
Day 14
Day 21
Day 28
SORT000016
(Liver SORT)
SORT000008
(Lung SORT)

Fig. 9A




Fig. 9B




Fig. 9C




Fig. 10A




Fig. 10B

Examples

Single Dose in RHFs	Formulation Optimization	Single Dose in NHPs	Dose Finding & Repeat Dose Studies in NHPs	
a low exposure dose (0.1 mg/kg), observe: 1) good lung distribution of the mRNA 2) DNAI1 protein expression in the target cells 3) tolerability findings that support additional dose finding and repeat dosing studies **Two LNPs tested:** • 5-component SORT • 4-component dLNP	• Enable long term storage & improve shipping conditions, achieve freezing buffers, increase stability • Decrease dose: SORT lipids with higher potency and better cell tropism characteristics • Shorten nebulization times: increase concentration, reduce lipid load • Further increase tolerability: reduce lipid load	• Assess higher doses • Assess longer timepoints for recovery (e.g., 72 and 144 hrs)	• Determine clinical candidate for IND enabling studies • Determine dose and dosing frequency • Determine max tolerated dose • Select nebulization device for clinical development **Studies:** • Single & multiple dose studies to be conducted with lead formulations • Repeat dose in NHPs • **Readouts:** • PK • Tolerability • Biodistribution • Immunological	• Safety/tox study in rats • Safety/tox study in NHPs

Fig. 10C




Fig. 10D




Fig. 10E

Functional Restoration and Delivery to NHPs (non-human primate) Achieved, e.g.,
FUNCTIONAL RESTORATION
WELL-TOLERATED IN MICE
SUCCESSFUL DELIVERY IN NHPs
✓ Repeat administration well tolerated
✓ Cellular uptake in the presence of mucus
✓ Normal beat frequency recovered
✓ Synchronized wave-like motion restored
✓ Activity comparable to normal controls
✓ Single administration, escalating dose well tolerated
✓ Good distribution and high levels of protein expression
✓ Histopathology results similar to vehicle
✓ Single dose, nebulization
✓ Target delivered dose achieved
✓ Well tolerated in all animals tested[1]
✓ Good distribution of mRNA
✓ DNAI1 protein detected
Green: Acetylated alpha-tubulin (cilia marker)
Red: Nuclei (DAPI)
[1] Based on lack of acute response and initial blood, BAL fluid, cytokine and histopathology data.

Fig. 11A




Fig. 11B




Fig. 12



epithelial cells
club cells
goblet cells
basal (stem) cells
EpCAM
SCGB1A1
MUC5AC
CK5
AC-Tubulin
100µm

Fig. 13A




Fig. 13B




Fig. 14A




Fig. 14B




Fig. 14C




Fig. 14D




Fig. 14E




Fig. 15




Newly-translated DNAI1 Protein Expression in Target Cells of the Respiratory Epithelium of NHPs
epithelial cells
ciliated cells
club cells
basal cells
Single 0.4 mg/kg administration of inhaled LNP-formulated DNAI1-HA mRNA with lung sections collected from two NHPs 6 hrs after dosing.
%DNAI1-HA Positive
0
2
4
6
Vehicle
DNAI1 mRNA
Treatment
Note: % DNAI1-HA positive calculated by combining cell counts from 4 examined lung sections. Total number of cells counted: ~500,000 to 1,400,000.

Fig. 16A

mIF Panel Results for NHP Lung Samples: DNAI1-HA Is Expressed in Cells of the Respiratory Epithelium



- DNAI1-HA expression detected in lung samples from NHPs treated with RTX0001.
- DNAI1-HA expression co-localized with markers for epithelial cells, including the club, basal and ciliated cells (club and basal cells are precursors for ciliated cells).
- No staining detected in lung samples from NHPs treated with RTX0004.

Fig. 16B



Bronchi
%DNAI1-HA Positive
0
10
20
30
40
Epithelial Cells
Ciliated Cells
Club Cells
Basal Cells
Goblet Cells
Vehicle
DNAI1 mRNA
Lung
%DNAI1-HA Positive
0
2
4
6
8
Approximate level achieved after a single annual dose of RTX0001 in ISEs, which led to restoration of ciliary activity
Epithelial Cells
Ciliated Cells
Club Cells
Basal Cells
Goblet Cells
Vehicle
DNAI1 mRNA

Fig. 17

STUDY GOALS	PARAMETERS	READOUTS
Compare multiple LNP formulations for: 1) biodistribution 2) expression in target cells 3) initial tolerability	NHPs intubated and ventilated to ensure consistent delivered dose for comparison between formulations	Readouts/necropsy at 6 and 24 hrs post administration
Looking for: • Good lung distribution of mRNA & protein • Confirm DNAH1-HA protein expression in target cells • Tolerability findings that support further dose finding and repeat dosing studies	Model: Cynomolgus macaques Treatment: • Short exposure, ≤ 8 minutes • Single low dose < 6 mg/kg Formulations: • LNP Device: Aerogen solo	Distribution: ISH & IF (mRNA & protein) Expression in target cells: multiplex IF Tolerability: • Clinical pathology • Histopathology • Cytokines • Complement activation • Hematology

Fig. 18A




Fig. 18B

No#	Designation (min)	Target dose TD (mg/kg)	Aerosol concentration E_c (ug/L)	RMV (L)	BW (kg)	Delivered dose (mg/kg)	Animals
1	Vehicle 90	0	0	1.638	3.2	0	Male
				1.417	2.7	0	Female
2	Low 30	0.08	7.62 +/- 0.369 (5.2)	1.550	3.0	0.12	Male
				1.462	2.8	0.12	Female
4	High 90	0.24	8.22 +/- 0.741 (5.2)	1.594	3.1	0.38	Male
				1.506	2.9	0.38	Female

0.38 mg/kg → 1.14 mg -25%-> 285 µg (RNA) → 8.55 mg total lipids

Fig. 18C

	Impactor (Mercer)	
RTX-00052/DNAI1	MMAD (µm)	GSD
2	1.7	1.88
3	2.3	1.92

Fig. 19A




Fig. 19B




Fig. 19C




Fig. 20A




Anti-HA:
Std 1.9 pg
0.38 mg/kg 6 h
Vehicle 24 h
3001
3501
3003
50 µg protein/lane
10 min exposure
Std 1.9 pg
Vehicle 24 h
1001 Cd
1501 Cr
0.38 mg/kg 24 h
3002
3502
0.38 mg/kg 72 h
Vehicle 24 h
Std 1.9 pg
Anti-DNAJ1:
1001
1501
50 µg protein/lane
3-5 min exposures

Fig. 20B

Vehicle 24 h

Animal Number	ELISA Result (ng/100 µg total protein)	Western Blot Signal (Y/N)
1001 Cr	n.d.	N
1001 Mi	n.d.	N
1501 Cr	n.d.	N



Est. LOQ: 5 pg/ml, 0.5 pg/well

High Dose: 0.38 mg/kg 6 h

Animal Number	ELISA Result (ng/100 µg total protein)	Western Blot Signal (Y/N)
3001 Cr	n.d.	N
3001 Mi	n.d.	N
3001 Cd	n.d.	N
3501 Cr	n.d.	N
3501 Mi	n.d.	N
3501 Cd	0.43*	N

High Dose: 0.38 mg/kg 24 h

Animal Number	ELISA Result (ng/100 µg total protein)	Western Blot Signal (Y/N)
3002 Cr	n.d.	N
3002 Mi	n.d.	N
3002 Cd	n.d.	N
3502 Cr	n.d.	N
3502 Mi	n.d.	N
3502 Cd	n.d.	N

High Dose: 0.38 mg/kg 72 h

Animal Number	ELISA Result (ng/100 µg total protein)	Western Blot Signal (Y/N)
3003 Cr	n.d.	N
3003 Mi	n.d.	N
3003 Cd	n.d.	N
3503 Cr	n.d.	N
3503 Mi	n.d.	N
3503 Cd	n.d.	N

*Below LOQ

- Only detected signal in one 6 h sample (Below LOQ of assay)
- Did not correlate with western blot results

Fig. 21A



Aspartate Aminotransferase (AST)
AST (IU/L)
Alkaline Phosphatase (ALP)
ALP (IU/L)
Alanine Aminotransferase (ALT)
ALT (IU/L)
Pre-T
6 h
24 h
72 h
168 h
No significant changes in AST, ALT, or ALP seen following treatment with RTX0052.

Fig. 21B




Fig. 21C






Fig. 21D



- Small increase in serum IL-6 levels seen with treatment.
- No significant changes seen in IP-10 or MCP-1 levels
- All cytokine levels were in the same range as normal reported levels

Fig. 21E



- Small increase in serum IL-6 levels seen with treatment. Levels were much
- No significant changes seen in IP-10 or MCP-1 levels

Fog. 21F




Fig. 21G





Fig. 22A



G = gravimetric analysis

Fig. 22B




Fig. 22C

No#	Designation (min)	Target dose TD (mg/kg)	Aerosol concentration C, (ug/L)	RMV (L)	BW (kg)	Delivered dose (mg/kg)	Animals
1	Vehicle 240	0	0	0.224	0.310	0	Male
				0.158	0.205	0	Female
2	Low 60	0.25	5.44 +/- 0.369 (5.5)	0.223	0.308	0.24	Male
				0.153	0.198	0.25	Female
3	Mid 120	0.49	5.50 +/- 0.585 (5.5)	0.255	0.311	0.48	Male
				0.156	0.203	0.51	Female
4	High 240	0.99	6.70 +/- 0.741 (5.5)	0.227	0.315	1.16	Male
				0.161	0.210	1.23	Female

Fig. 22D

	Impactor (Mercer)	
RTX00052/DNAI1-HA	MMAD (µm)	GSD
2	1.3	1.97
3	1.1	2.00
4	1.4	1.89

Fig. 23A




Fig. 23B




Fig. 23C




Fig. 24A




Anti-HA:
Anti-DNAI1:
6 h Necropsy
Group 1
Vehicle
Group 4
1.2 mg/kg
Std
3.9 pg
Std
1.3 pg
40 ug total protein per lane
10 min exposure
6 h Necropsy
Group 1
Vehicle
Group 4
1.2 mg/kg
Std
1.3 pg
50 ug total protein per lane
10 min exposure
24 h Necropsy
Group 1
Vehicle
Group 4
1.2 mg/kg
Std
1.3 pg
50 ug total protein per lane
10 min exposure
40 ug total protein per lane
2.5 min exposure
50 ug total protein per lane
2.5 min exposure
50 ug total protein per lane
2.5 min exposure

Fig. 24B

Vehicle 24 h			High Dose: 1.2 mg/kg 6 h			High Dose: 1.2 mg/kg 24 h		
Animal Number	ELISA Result (pg/100 µg total protein)	Western Blot Signal (Y/N)	Animal Number	ELISA Result (pg/100 µg total protein)	Western Blot Signal (Y/N)	Animal Number	ELISA Result (pg/100 µg total protein)	Western Blot Signal (Y/N)
1001	n.d.	N	4001	0.47	Y	4006	n.d.	N
1002	n.d.	N	4501	n.d.	Y	4506	n.d.	N
1003	n.d.	N	4002	n.d.	N	4007	n.d.	N
1501	n.d.	N	4502	1.10	Y	4507	n.d.	N
1502	n.d.	N	4003	3.23	Y	4008	n.d.	N
1503	n.d.	N	4503	n.d.	N	4508	n.d.	N
			4004	0.34*	Y	4009	n.d.	N
			4504	1.01	Y	4509	n.d.	N
			4005	0.09*	N	4010	n.d.	N
			4505	n.d.	N	4510	n.d.	N

*Below LOQ



Est. LOQ: 5 pg/ml, 0.5 pg/well

Good correlation with WB results: 5/6 WB+ samples are also ELISA+

Fig. 25A




Fig. 25B




Fig. 25C




Fig. 25D




Fig. 26A

Group	Formulation	Animals	Delivery	[RNA] (mg/mL)	Test Dose	Amount Delivery of Substrate	# animals	Data Collection
1	Control vehicle	Albino B6 ; naive	Nebulization 2 h 66.6 µL/min	none	4 mL buffer 27	-	n = 12	For groups 2 to 7 – once a week (Monday or Tuesday) post dose: 3) 3 mice @ 4h post dosing = IVIS For all groups – after last dose @ 2 mice @ 4h post last dose and post IVIS = perfuse and explant liver, spleen and lungs. Half for RNA later, half for protein assay b) repeat at 72h post last dosing @ 2 mice and 7 days post dosing (3 mice)
2	RT-X00001 (69% DMA1-HA + 5% luciferase mRNA)	Albino B6 ; naive	Nebulization 2 h 66.6 µL/min	0.5 mg/mL rab: 0.5 mg/mL	4.0 mg per chamber	For 2 mice 2 mL Luciferin @ 95 mM (30 mg/mL)	n = 12	
3	RT-X00001 (69% DMA1-HA + 5% luciferase mRNA	Albino B6 ; naive	Nebulization 2 h 66.6 µL/min	0.5 mg/mL rab: 0.5 mg/mL	4.0 mg per chamber	For 2 mice 2 mL Luciferin @ 95 mM (30 mg/mL)	n = 12	
4	RT-X00002 (69% DMA1-HA + 5% luciferase mRNA	Albino B6 ; naive	Nebulization 2 h 66.6 µL/min	0.5 mg/mL rab: 0.5 mg/mL	4.0 mg per chamber	For 2 mice 2 mL Luciferin @ 95 mM (30 mg/mL)	n = 12	

Fig. 26B



Groups 1 and 2
Groups 3 and 4
Days
2 mice
Perfused and lungs, liver and spleen explanted for mRNA and protein detection
72 h
7 days
5 mice
5 mice
Histopathology

Fig. 27A



lungs IVIS
Average Radiance
photons/s/cm²/sr (median ± r.)
5×10⁴
4×10⁴
3×10⁴
2×10⁴
1×10⁴
0
Dose 2
Dose 4
Dose 6
Dose 8
RTX00001
RTX00051
RTX00052
Day 1

Fig. 27B



RTX000001
RTX000051
RTX000052
Whole body IVIS
Average Radiance
photons/s/cm²/sr (median ± r.)
4×10⁴
3×10⁴
2×10⁴
1×10⁴
0
Dose 2
Dose 4
Dose 6
Dose 8
211
212
311
312
411
412
Dose 2
Dose 4
Dose 6
Dose 8

Fig. 27C




Fig. 27D




Fig. 27E




Fig. 28A





Fig. 28B


	APS (Aerodynamic particle sizer)				Impactor (Marcer)	
	MMAD (μm)		GSD		MMAD (μm)	GSD
	Pre	Post	Pre	Post		
RTX0001	2.59	2.21	1.69	2.23	2.55	1.86
RTX0051	3.33	1.95/2.16	1.93	1.77/2.22	n.d.	n.d.
RTX0052	2.96	2.99	1.83	1.86	2.57	1.80

Fig. 28C



Bin #	Scoring
Bin 0	0 copies/cell or no staining
Bin 1	1-3 copies/cell
Bin 2	4-9 copies/cell and none/few clusters
Bin 3	10-15 copies/cell and/or <10% dots in clusters
Bin 4	>15 copies/cell and/or >10% dots in clusters

Fig. 28D



H-Score Definition:
H- score = Σ[Bin 0-4] (bin number x percentage of cells per bin)

Range: 0 to 400

Fig. 29A




Fig. 29B




Fig. 29C




Fig. 29D




Fig. 30A




Fig. 30B




Fig. 30C




Fig. 30D




Fig. 30E




Fig. 30F



Trachea - Block 8E
%DNAI1-HA Positive
All Cells
Epithelial Cells
Ciliated Cells
Club Cells
Basal Cells
Goblet Cells
All Cells
Epithelial Cells (EpCAM+)
Ciliated Cells (Ac-Tub+)
Club Cell (SCGB1A1+)
Basal Cells (CK5+)
Goblet Cells (MUC5AC+)
Vehicle
RTX-00001
RTX-00051
RTX-00052
Single 0.4 m
of inhaled LN
DNAI1-HA m
Tracheal sec
two NHPs 6

Fig. 31A




Fig. 31B




Fig. 31C




Fig. 31D




Fig. 31E




Fig. 32A




Fig. 32B




Fig. 32C




Fig. 32D




Fig. 32E




Fig. 33



Blood Neutrophils
Neutrophils (10³/ml)
Baseline
6 h Post-Treatment
72 h Post-Treatment
Vehicle (72 h)
RTX00051 (6 h)
RTX00051 (72 h)
RTX00052 (6 h)
RTX00052 (72 h)
BAL Neutrophils
Neutrophils (10³/ml)
Baseline
Post-Treatment
Vehicle (72 h)
RTX00051 (6 h)
RTX00051 (72 h)
RTX00052 (6 h)
RTX00052 (72 h)
Blood WBCs
WBC (10³/ml)
Baseline
6 h Post-Treatment
72 h Post-Treatment
Vehicle (72 h)
RTX00051 (6 h)
RTX00051 (72 h)
RTX00052 (6 h)
RTX00052 (72 h)

Fig. 34



AST
AST (IU/L)
Creatine Kinase
Creatine Kinase (IU/L)
LDH
LDH (IU/L)
Selected measurements shown had a ≥2-fold change from baseline

Fig. 35

6 hr Necropsy Scores

6 HRS	01		S1		S2	
	M	F	M	F	M	F
Alveolar macrophages, increased	0	0	0	0	0	1
Infiltrate, mixed, interstitial	1	0	0	0	0	0
Infiltrate, mixed, terminal bronchiole						
Inflammation, mixed, alveolar, multifocal						
Inflammation, mixed, interstitial, multifocal						
Inflammation, mixed, terminal bronchiole						
Inflammation, neutrophilic, alveolar, multifocal	3	2	1	2	3	3
Inflammation, neutrophilic, terminal bronchiole	1	1	1	0	2	2
Ulceration, bronchiole	0	0	0	0	1	0

72 hr Necropsy Scores

72 HRS	vehicle		01		S1		S2	
	M	F	M	F	M	F	M	F
Alveolar macrophages, increased	1	1	0	0	0	0	0	0
Infiltrate, mixed, interstitial	1	1	0	0	0	2	0	0
Infiltrate, mixed, terminal bronchiole	0	1	0	0	0	0	0	0
Inflammation, mixed, alveolar, multifocal	0	0	3	3	0	0	3	2
Inflammation, mixed, interstitial, multifocal	0	0	0	2	0	0	2	2
Inflammation, mixed, terminal bronchiole	0	0	0	1	0	0	0	0
Inflammation, neutrophilic, alveolar, multifocal	0	0	0	0	3	2	0	0
Inflammation, neutrophilic, terminal bronchiole	0	0	1	0	2	0	0	0

Fig. 36A






Fig. 36B



APS		
Sample	MMAD (µm)	GSD
1	1.22	1.64
2	1.21	1.64
3	1.2	1.68
Average	1.21	1.65
Std Dev	0.01	0.02
%RSD	1%	1%

APS		
Sample	MMAD (µm)	GSD
1	1.72	1.82
2	1.72	1.76
3	1.78	1.83
Average	1.74	1.80
Std Dev	0.03	0.04
%RSD	2%	2%

APS		
Sample	MMAD (µm)	GSD
1	2.34	2.13
2	2.23	2.03
3	2.12	1.95
Average	2.23	2.04
Std Dev	0.11	0.09
%RSD	5%	4%


RTX0001/DNAI1-HA mRNA
0.15
0.10
0.05
0.00
mg/kg
2001
2002
2003
2004
NHP ID#



RTX0004/DNAI1-HA mRNA
0.15
0.10
0.05
0.00
mg/kg
2005
2006
2007
2008
NHP ID#

Fig. 38A



MDA-MB-231 tumor
Percent of Score 0
Percent of Score 1+
Percent of Score 2+
Percent of Score 3+
Percent of Score 4+
Skin 1
Skin 2
Vehicle
6h
24h
MDA-MB-453 tumor
Percent of Score 0
Percent of Score 1+
Percent of Score 2+
Percent of Score 3+
Percent of Score 4+
Skin 1
Skin 2
Vehicle
6h
24h

Fig. 38B

UPDATED – FINAL ISH RESULTS FOR RTX0001

Bin #	Scoring
Bin 0	0 copies/cell or no staining
Bin 1	1-3 copies/cell
Bin 2	4-9 copies/cell and none/few clusters
Bin 3	10-15 copies/cell and/or <10% dots in clusters
Bin 4	>15 copies/cell and/or >10% dots in clusters




Fig. 38C



Vehicle
RTX0001/DNAJL1-HA mRNA
RTX0004M/DNAJL1-HA mRNA
1001/hDNAJ1
1002/hDNAJ1
2001/hDNAJ1
2002/hDNAJ1
2003/hDNAJ1
2004/hDNAJ1
2005/hDNAJ1
2006/hDNAJ1
2007/hDNAJ1
2008/hDNAJ1
6 hrs
24 hrs
Blue = nuclei (DAPI), Red = DNAJL-HA (anti-HA)

Fig. 39A




Fig. 39B




Fig. 39C



epithelial cells
respiratory epithelium
club cells
goblet cells
basal (stem) cells
ciliated cells
EpCAM
SCGB1A1
MUC5AC
CK5
AC-Tubulin
100µm
100µm
100µm
100µm
100µm

Fig. 40A




Fig. 40B

